Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) was founded in 1989 and was formerly known as Isis Pharmaceuticals, Inc. (original code NASDAQ:ISIS). It did not avoid confusion with the terrorist organization ISIS. Changed to its current name in December 2015, headquartered in California, USA, with 435 full-time employees. It is an enterprise focusing on the development of a new generation of human compound treatments. The company’s chemical compounds are suitable for various diseases, such as Crohn’s disease, Psoriasis, asthma and other cancers, etc.; in addition, the company’s medicinal chemistry and biology research projects also support the delivery of antisense and small molecule drugs.
Ionis Pharmaceuticals (IONS):
Ionis Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the exploration and development of RNA-based drugs for its product lines and its partners. The company’s drug development projects mainly focus on the treatment of cardiovascular and metabolic diseases, as well as cancer, inflammation and other diseases.
Ionis Pharmaceuticals mainly produces an antisense drug Vitravene for the treatment of cytomegalovirus retinitis in AIDS patients. The company and its partners are developing approximately 18 drugs, including Mipomersen (ISIS 301012), ISIS 113715, ISIS 325568 and ISIS 369645. The company focuses on the development and commercialization of microRNA therapy through a joint venture with Regulus Therapeutics LLC.
In addition, in July 2015, Ionis Pharmaceuticals also reached a strategic cooperation with AstraZeneca (AZN) to jointly develop therapies for cardiovascular, metabolic and renal diseases.
On July 14, 2017, Akcea Therapeutics, Inc., a subsidiary of Ionis Pharmaceuticals, which focuses on the development of therapeutic drugs for cardiometabolic diseases caused by lipid disorders , successfully listed on the Nasdaq IPO.